



## **CORE BRIEF TO MANAGEMENT GROUP MEMBERS**

### **MEETING HELD ON 24 JUNE 2021**

This briefing sets out the key areas of discussion and decision. It aims to ensure the Management Group members have a common core brief to disseminate within their organisation.

#### **1. Welcome and Introductions**

The Chair welcomed members to the meeting noting that, due to the COVID-19 pandemic, the meeting was being held via MS Teams. It was noted that a quorum had been achieved.

Written questions from members and answers had been published in advance of the meeting and had been embedded within the meeting papers.

#### **2. Action Log**

Members received an update on progress against the action log and noted the updates.

#### **3. Extracorporeal Membrane Oxygenation for Adults (ECMO)**

Members received a report that considered whether demand for Extracorporeal Membrane Oxygenation for Adults (ECMO) failure for the South West Wales population might potentially support repatriation of the service.

Members (1) noted that WHSSC had recently provided a paper to Welsh Government in relation to the provision of ECMO for the adult population of Wales and the potential viability of an ECMO centre based within South Wales, (2) noted the ECMO activity data, the assessment of whether there is unmet need, the evidence relating to minimum volumes required for a safe and sustainable service, and (3) noted the next steps to develop an ECMO service in South Wales would be as part of a future Integrated Commissioning Plan (ICP) process.

#### **4. Commissioning a Mesothelioma MDT**

Members received a paper outlining the case for establishing an all Wales specialist mesothelioma MDT commissioned by WHSCC, with a proposal that the scheme was included in the CIAG process for the ICP 2022-2023

Members (1) noted the incidence and outcomes for people in Wales, and the potential benefits of an all Wales mesothelioma MDT, (2) noted the

proposal to Joint Committee to transfer the commissioning of specialised mesothelioma from Health Boards to WHSSC, and (3) noted that the inclusion of a scheme for an all Wales mesothelioma MDT would be included in the Clinical Impact Assessment Group (CIAG) process for 2022-2023.

## **5. Percutaneous Mitral Valve Repair (PMVR)**

Members received a paper that sought approval for the release of funding to enable the implementation of the 2020-2023 ICP scheme for Percutaneous Mitral Valve Repair (PMVR).

Members (1) noted that the WHSCC ICP Prioritisation process panel had identified PMVR for primary degenerative mitral regurgitation in adults as the highest scoring priority for funding which was subsequently approved for inclusion in the WHSCC ICP 2020-2023, and (2) approved the release of funding to enable implementation of the 2020-2023 ICP scheme, noting that the funding was within the provision made in the ICP.

## **6. Policy Development to Support HTW Guidance**

Members received a report presenting a joint proposal by WHSSC and Health Technology Wales (HTW) to translate all HTW (including NICE MTG guidance) into a commissioning policy and the consideration of collective commissioning for some HTW guidance.

Members noted (1) the recommendation that all HTW non-medical technology guidance is translated into commissioning policies/and or service specifications where appropriate, subject to WHHSC methodology, (2) the application to Welsh Government for the funding of two posts to support the policy development work, (3) the development of a process for the collective (all Wales) commissioning of non-medical technology guidance facilitated by WHSSC, and (4) the proposal for HTW to confirm and define the future status of HTW and NICE MTG guidance (either 'adopt' or 'justify' mandated).

## **7. Activity Report for Month 12 2021-2022**

Members received papers that highlighted the scale of the decrease in activity levels during the COVID-19 period, and whether there are any signs of recovery in specialised services activity. These activity decreases were shown in the context of the potential risk regarding patient harms and of the loss of value from nationally agreed financial block contract arrangements.

Members noted the information presented in the report.

## **8. MG Annual Report 2020-2021**

Members received the Management Group Annual Report for the period April 2020-March 2021 which outlined the business activities of the group during that period.

Members noted the report and approved the MG Annual Report 2020-2021 from Chair of the Group for forward distribution to the Joint Committee for assurance.

## **9. Month 2 Finance Report 2021-22**

Members received a paper the purpose of which was to provide the current financial position of WHSSC together with the outturn forecast for the financial year. The financial position at month 2 was a year-end outturn under spend of £3,364k.

The majority of this under spend related to the English SLA forecast under spend which reflects the difference between the plan baseline and the agreed blocks for Q1 & Q2, 2020-2021 reserve releases and development slippage. There was a partial offset with the over spend in Mental Health at month 1 that included high CAMHS OOA activity and an exceptional high cost medium secure patient with the forecast to plan.

